Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term access to dolutegravir or Triumeq after parent pediatric HIV studies
PACTR202112842892883Phase 3Not yet recruiting
- Sponsor
- ViiV Healthcare
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of abacavir and dolutegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
abacavirdolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202112842892883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202112842892883.